| Abstrakt: |
A recent study conducted by researchers at Case Western Reserve University examined the characteristics, genetics, and outcomes of patients with acute myeloid leukemia (AML) and autoimmune diseases (AD). The study found that patients with AML and a prior history of AD had similar cytogenetic profiles and outcomes to those with therapy-related AML (t-AML), but with distinct molecular features. The findings suggest that the MAPK signaling pathway and spliceosome inhibitors may be potential areas of investigation for patients with AD-AML. Further research is needed to validate these findings in larger studies. [Extracted from the article] |
